...
机译:P1.01-101顺序治疗在屈服阳性蛋白酶抑制后顺序治疗的生存效益
National Cancer Center/cancer Hospital Chinese Academy of Medical Sciences and Peking Union;
Medical Oncology Cancer Institute and Hospital Chinese Academy of Medical Sciences Peking Union;
Medical Oncology Cancer Institute and Hospital Chinese Academy of Medical Sciences Peking Union;
Medical Oncology National Cancer Center/cancer Hospital Chinese Academy of Medical Sciences and;
National Cancer Center/cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical;
National Cancer Center/cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical;
National Cancer Center/cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical;
National Cancer Center/cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical;
机译:P1.01-101顺序治疗在屈服阳性蛋白酶抑制后顺序治疗的生存效益
机译:一线克唑替尼相对于标准化疗和二线克唑替尼在ALK阳性晚期肺腺癌中有无进展生存获益吗?中国患者回顾性研究
机译:在晚期ALK阳性NSCLC患者中,用crizotinib继续ALK抑制的临床益处超出了疾病的初始进展。
机译:用于预测免疫疗法治疗的高级NSCLC患者存活的三角洲 - 辐射瘤
机译:心脏移植患者多药抗性蛋白-1表达和功能的顺序分析:治疗抗急性排斥的可能机制
机译:顺序克唑替尼和赛瑞替尼治疗ALK阳性NSCLC患者的无进展生存期和总生存期
机译:用序贯屈曲肾上腺素和Ceritinib治疗的ALK阳性NSCLC患者的无进展和整体存活